LRLiucheng Rong

Liucheng Rong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Liucheng Rong has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Jie Huang

    Hematology and Oncology, Children's Hospital of Nanjing Medical University, Nanjing, China

    3 shared publications
  • Yongjun Fang

    Department of Hematology and Oncology, Children's Hospital of Nanjing Medical University, Nanjing, China.

    3 shared publications
  • Enxiu Wang

    Nanjing CART Medical Technology Co. Ltd, Nanjing, China

    1 shared publication
  • Jie Li

    Department of Infectious Diseases Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University Nanjing Jiangsu China

    1 shared publication
  • Jun Zhu

    Department of Interventional, The Second People’s Hospital of Yibin City, Yibin, China

    1 shared publication
  • Lizhen Huang

    Department of Materials Science & Engineering, CAS Key Lab of Materials for Energy Conversion, Anhui Laboratory of Advanced Photon Science and Technology, University of Science and Technology of China 1 , Hefei

    1 shared publication

Latest Publications

  • Open Access

    CLAG-M chemotherapy followed by umbilical cord blood stem cell transplantation for primary refractory acute myeloid leukaemia in a child: A case report

    by Jie Huang, Xiao-Yun Yang, Liu-Cheng Rong, Yao Xue, Jun Zhu, Yong-Jun Fang

    The prognosis of paediatric primary refractory/relapsed acute myeloid leukaemia (R/R AML) remains poor. Intensive therapy is typically used as salvage treatment for those with R/R AML. No data are currently available about the use of the CLAG-M protocol as salvage therapy in paediatric patients with R/R AML. An 8-year-old patient was diagnosed with acute myeloid leukaemia by bone marrow morphology and immunophenotype. The patient showed poor response to two cycles of induction therapy with 60% blast cells in the bone marrow after the second induction cycle. The patient achieved complete remission after being treated with the CLAG-M protocol as salvage therapy before undergoing umbilical cord blood stem cell transplantation. Morphological complete remission with haematological recovery has hitherto been maintained over 4 mo. Abnormal gene mutations detected at diagnosis were undetectable after haematopoietic stem cell transplantation. Here we present a paediatric patient with primary refractory acute myeloid leukaemia who was successfully treated with the CLAG-M protocol. Given the positive results of the presented patient, large-scale clinical studies are required to assess the role of the CLAG-M protocol in the salvage treatment of refractory or relapsed AML in childhood.


  • Pseudoprogression of Extramedullary Disease in Relapsed Acute Lymphoblastic Leukemia After CAR T-cell Therapy

    by Jie Huang, Liucheng Rong, Enxiu Wang, Yongjun Fang

    Background: CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has emerged as a powerful immunotherapy in relapsed or refractory B-cell acute lymphoblastic leukemia. The changes in extramedullary (EM) disease in pediatric relapsed or refractory B-cell acute lymphoblastic leukemia after CAR T-cell therapy have rarely been reported. Materials & methods: A child with relapsed B-ALL was treated with CAR T-cell therapy. Bone marrow morphological examination, minimal residual disease, fusion mutation and radiological evaluation of the EM disease were performed before and after CAR T-cell infusion. Results: Radiological assessment revealed a distinct asymptomatic pseudo progression of EM involvements on day 16 after CAR T-cell infusion. Conclusion: Pseudoprogression of EM disease indicates heterogeneous immune-related patterns of response in patients treated with CAR-T therapy. Such patients should be closely monitored and practical immune-related response criteria should be developed for them.


  • Association of genetic variations inmTORwith risk of childhood acute lymphoblastic leukemia in a Chinese population

    by Lizhen Huang, Jie Huang, Peng Wu, Qian Li, Liucheng Rong, Yao Xue, Qin Lu, Jie Li, Na Tong, Meilin Wang, et al.

    The mammalian target of rapamycin (mTOR) is an important protein kinase regulating cell survival and apoptosis. To determine whether genetic variations in mTOR are associated with risk of acute lymphoblastic leukemia (ALL) in Chinese children, we genotyped two tag single nucleotide poymorphisms (SNPs) in mTOR (rs2536 and rs2295080) in a case-control study. We observed that the variant genotype TC of mTOR rs2536 was associated with a significantly decreased risk of childhood ALL (adjusted odds ratio [OR] = 0.67, 95% confidence interval [CI] = 0.46-0.96), and the association was more pronounced in high-risk ALL and T-phenotype ALL groups. Additionally, we found that the combined genotypes TC/CC decreased the risk of ALL only in the high-risk ALL group (adjusted OR = 0.54, 95% CI = 0.32-0.91) and T-phenotype ALL group (adjusted OR = 0.29, 95% CI = 0.10-0.84). These results suggest that the mTOR rs2536 polymorphism is involved in the susceptibility to childhood ALL in a Chinese population.